Sleep

Theresa Juday, RPh, director, Specialty Product Development, CVS Health, discusses the potential of cognitive behavioral therapy to address health disparities in underserved communities.

School closures during the first wave of the COVID-19 pandemic in Switzerland were linked with longer sleep duration and improved health-related quality of life in high school students.

The top 5 most-read sleep articles of 2021 on AJMC.com covered emerging therapies in the treatment of obstructive sleep apnea and idiopathic hypersomnia, the effects of antidepressant use on rapid-eye movement sleep, and the sleep-related effects of COVID-19.

Michael Thorpy, MD, director, Sleep-Wake Disorders Center, Montefiore, and professor of neurology, Albert Einstein College of Medicine, discusses treatment implications for clinicians managing chronic insomnia and potential comorbid conditions.

People experiencing teeth grinding or clenching during sleep, called sleep bruxism, were found to be more likely than the general population to report incidence of other sleep disorders, such as obstructive sleep apnea and restless leg syndrome.

Daniel Greer, PharmD, BCPP, clinical assistant professor, Rutgers Ernest Mario School of Pharmacy, speaks on how capabilities of cognitive behavioral therapy have evolved to a more user-friendly approach in the management of chronic insomnia.

Patients with obstructive sleep apnea (OSA) exhibited similarly improved insomnia and quality-of-life outcomes when administered hypoglossal nerve stimulation (HNS) vs standard-of-care positive airway pressure (PAP) therapy.

Theresa Juday, RPh, director, Specialty Product Development, CVS Health, discusses the indirect and direct cost burden associated with chronic insomnia.

Financial hardship was found to be a significant risk factor for worse sleep quality in patients with concomitant obstructive sleep apnea (OSA) and type 2 diabetes (T2D)

Michael Thorpy, MD, director, Sleep-Wake Disorders Center, Montefiore Medical Center, and professor of neurology, Albert Einstein College of Medicine, speaks on the common occurrence of other comorbidities in patients with chronic insomnia.

A mobile app was shown to be feasible in identifying risk of obstructive sleep apnea and associated symptoms, as well as promoting management recommendations among an outpatient cohort.

Ian J. Neeland, MD, FACC, FAHA, is co-director of the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease for University Hospitals Harrington Heart & Vascular Institute and director of the UH Center for Cardiovascular Prevention, in the Cleveland, Ohio, area. Here, he explains how sodium-glucose co-transporter 2 (SGLT2) inhibitors can treat metabolic physiologic effects of sleep apnea.

In Icelandic patients, obstructive sleep apnea were associated with a 2-fold increased risk of severe COVID-19 that required hospitalization or led to death after accounting for obesity and other comorbidities.

Daniel Greer, PharmD, BCPP, clinical assistant professor, Rutgers Ernest Mario School of Pharmacy, discusses the use of cognitive behavioral therapy (CBT) as a first-line treatment for chronic insomnia and barriers limiting its use.

Patients with asthma were found to have a more than 3-fold greater risk of developing narcolepsy than those without asthma, with use of inhaled corticosteroids indicated to decrease risk.

Theresa Juday, RPh, director, Specialty Product Development, CVS Health, speaks about the barriers affecting uptake of cognitive behavioral therapy (CBT) as a first-line treatment for insomnia.

Findings of an abstract presented at CHEST 2021 indicated that antidepressant use was associated with increased REM sleep latency and a complete lack of REM sleep, which may contribute to the poorer quality-of-life scores observed in these patients.

Daniel Greer, PharmD, BCPP, clinical assistant professor, Rutgers Ernest Mario School of Pharmacy, speaks on at-risk populations of chronic insomnia, and the reciprocal relationship between the condition and other comorbidities.

An abstract presented at CHEST 2021 showed that women who entered pregnancy with sleep-disordered breathing were associated with higher levels of insulin resistance and potential risk of gestational diabetes.

Patients with obstructive sleep apnea with adequate continuous positive airway pressure (CPAP) therapy adherence exhibited significant reductions in diastolic blood pressure long term, compared with counterparts with poor adherence.

Theresa Juday, RPh, director, Specialty Product Development, CVS Health, discusses how payer interest in the use of cognitive behavioral therapy for insomnia has grown in recent years.

Two abstracts presented at the CHEST Annual Meeting 2021 showed that patients with narcolepsy treated with once-nightly sodium oxybate, FT218, vs placebo exhibited significant improvements in sleep latency and cataplexy.

Daniel Greer, PharmD, BCPP, clinical assistant professor, Rutgers Ernest Mario School of Pharmacy, discusses the incidence and long-term implications of chronic insomnia.

Older individuals with a weekday bedtime later than midnight were associated with a greater risk of myocardial infarction. No elevated risks were observed according to weekend bedtimes.

Wearable accelerometer data from over 89,000 participants indicated that people with a mental illness diagnosis were more likely to have poor sleep quality than the general population.